Serum CA 15.3, CEA and ESR patterns in breast cancer

International Journal of Biological Markers

Volumn 12, Issue 4, 1997, Pages 168-173

  Rubach, M ^a   Szymendera, J J ^a   Kaminska J ^a   Kowalska, M ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Breast cancer; CA 15.3; Carcinoembryonic antigen (CEA); ESR; Prognosis

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; REGRESSION ANALYSIS;

EID: 0031409928     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200406     Document Type: Article

References (31)

1. Zatoński W, Tyczyński J, Nowotwory Zlośliwe w Polsce w 1993 roku. Centrum Onkologii-Instytut Warszawa 1996.
2. Fox MS. On the diagnosis and treatment of breast cancer. JAMA 1979; 241: 489-95.
3. Nemoto T, Vana J, Bedvani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917-25.
4. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: Implication for systemic therapy. Cancer Res 1979; 44: 3643-53.
5. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1.015 breast cancer patients. J Clin Oncol 1987; 5: 55-61.
6. Molina R, Zanon G, Filella X et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36: 41-8.
7. Bombardieri E, Pizzichetta M, Veronesi et al. CA 15.3 determination in patients with breast cancer: Clinical utility for the detection of distant metastases. Eur J Cancer 1993; 29A: 144-6.
8. Al-Jarallah MA, Behbehani AE, El-Nass SA, et al. Serum CA 15.3 patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 1993; 19: 74-9.
9. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA 15.3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48: 4107-12.
10. Robertson JFR. Prospective confirmation of a biochemical index for measuring therapeutic efficacy in metastatic breast cancer in a multicentre study. The Breast 1996; 5: 372-3.
11. Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Koivula T. Serum CA 15.3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988; 58: 213-5.
12. Colomer R, Rubal A, Salvador L. Circulating tumour marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989; 64: 1674-81.
13. Wang DY, Knyba RE, Bulbrook RD, Millis RR, Hayward JL. Serum carcinoembryonic antigen in the diagnosis and prognosis of women with breast cancer. Eur J Cancer Clin Oncol 1984; 20 (1): 25-31.
14. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15.3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A; 1994 (14): 2082-4.
15. Cohen AD, Gopas J, Karplus G, Cohen Y. CA 15.3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. Israel J Med Sciences 1995; 31: 155-9.
16. Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic antigen expression in stage I and II breast cancer: its relationship with clinicopathologic factors. Human Pathol 1996; 27: 297-301.
17. Pectasides D, Pavlidis N, Gogou L et al. Clinical value of CA 15.3, mucin-like carcinoma-associated antigen, tumour polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 1996; 19 (5): 459-64.
18. Pyke CM, Menezes G, Purdie DM, Johnson S, Cowley D. Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer? Australian & New Zealand J Surg 1997; 67 (65): 256-9.
19. Horobin JM, Browning MCK, McFarlane NP et al. Potential use of tumor marker CA 15.3 in the staging and prognosis of patients with breast cancer. J R Coll Surg Edinb 1991; 36: 219-21.
20. Wojtacki J, Dziewulska-Bokiniec A, Kowalski DM, Zóltowska A, Ciesielski D, Suszko M. Serum CA 15.3 antigen - a prognostic factor in breast cancer patients? Przegla̧d Lekarski 1996; 53 (11): 788-92.
21. O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA 15.3 measurement in primary breast carcinoma. Br J Cancer 1995; 71: 1288-91.
22. Dixon AR, Jonrup I, Jackson L, Chan SY, Badley RA, Blamey RW. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA and CA 15.3: fact or fiction? Disease Markers 1991; 9: 167-74.
23. Robertson JFR, Pearson D, Price MR, Selby C, Blamey RW, Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 1991; 64: 757-63.
24. Dixon AR, Jackson L, Chan SY, Badley RA, Blamey RW. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer 1993; 68: 181-5.
25. Namer M, Fumoleau P, Ricolleau G et al. Usefulness of tumour markers in bone metastases of breast cancer: prediction, diagnosis and prognosis therapeutic management (abstract). J Tumour Marker Oncol 1991; 6: 56.
26. Gion M, Mione R, Nascimben O et al. The tumour associated antigen CA 15.3 in primary breast cancer. Evaluation of 667 cases . Br J Cancer 1991; 63: 809-13.
27. Bhatavdecar JM, Petel DD, Karelia NH et al. Tumour markers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Cancer Res Treat 1994; 30: 293-7.
28. van Dalen A. Pre-operative tumour marker levels in patients with breast cancer and their prognosis. Tumor Biol 1990; 11: 189-95.
29. Esteban JM, Felder B, Chul A, Simpson JF, Battifora H, Shively JE. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994; 74: 1575-83.
30. Tampellini M, Berruti A, Gerbino A et al. Relationship between CA 15.3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997; 75: 698-702.
31. Albuquerque KV, Price MR, Badley RA, et al. Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol 1995; 21: 504-9.